Zeta CDX2 Antibody. Zeta’s recombinant rabbit antibody recognizes CDX2, a homeobox gene that encodes a nuclear transcription factor critical for intestinal embryonic development that is relatively specific for intestinal epithelium.
CDX2 is a fairly specific marker of GI origin for adenocarcinomas, but also stains selected adenocarcinomas of other sites indicated below and can use to determine origin of metastatic adenocarcinoma as part of panel. CDX2 can distinguish primary and secondary colorectal adenocarcinomas and primary bladder adenocarcinoma from colorectal carcinoma extending / metastatic to bladder. CDX2 can also distinguish mucinous bronchioloalveolar adenocarcinoma (CDX2-) from metastatic mucinous colorectal adenocarcinoma.
The intestine-specific transcription factors CDX1 and CDX2 are important for directing intestinal development, differentiation, proliferation and maintenance of the intestinal phenotype. CDX2 protein expression has been seen in GI carcinomas. The CDX2 antibody has been useful to establish GI origin of metastatic adenocarcinomas and carcinoids and is especially useful to distinguish metastatic colorectal adenocarcinoma from lung adenocarcinoma. However, mucinous carcinomas of the ovary also express CDX2 protein, which limits the usefulness of this marker in the distinction of metastatic colorectal adenocarcinoma from mucinous carcinoma of the ovary.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.